Misonix BoneScalpel(TM) Subject Of New Clinical Paper
FARMINGDALE, N.Y., Jan. 29, 2013 /PRNewswire via COMTEX/ -- Misonix, Inc.
(nasdaqgm:MSON), an international surgical device company that designs,
manufactures and markets innovative therapeutic ultrasonic products for spine
surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery,
laparoscopic surgery and other surgical applications, was cited in a clinical
paper accepted for publication by "The Laryngoscope," a prestigious,
peer-reviewed journal circulated to leading ear, nose, throat and reconstructive
surgeons, entitled "Piezoelectric BoneScalpel Osteotomies in Osteocutaneous Free
Flaps," authored by Wick, et al, from the Department of Otolaryngology-Head and
Neck Surgery, University Hospitals Ear, Nose, and Throat Institute; University
Hospitals Case Medical Center, Cleveland, Ohio. Free flaps, in this instance,
refer to harvested bone and soft tissue from donor sites used in reconstructive
surgery of the head and neck.
Among the conclusions of the study, it was noted that the Misonix BoneScalpel
Ultrasonic Bone Cutter offers a safe and efficient method to create precise cuts
during the harvest of bone to be used for reconstructive surgery of the head and
neck, generally required as a result of cancer surgery. Primary advantages of the
device include better tactile control, precise osteotomies (cuts through bone), a
minimal learning curve for the surgeons, and theoretic protection of vital soft
tissue such as vascular structures.
The Misonix BoneScalpel, which was used to perform the study, is a novel
ultrasonic osteotome (bone cutting device) used for safe, tissue-selective bone
dissection that encourages non-fragmented bone removal and refined osteotomies
while sparing elastic soft tissue structures. Most users report that the surgical
field is relatively bloodless and clean. Loss of viable bone is minimal and
controllable. The BoneScalpel has been used extensively for bone removal in the
cervical, thoracic and lumbar spine, including deformity surgery.
"We are proud to be cited by a prestigious peer-reviewed journal for yet another
positive clinical experience with the Misonix BoneScalpel when used in advanced
head and neck surgery," said Michael A. McManus, Jr., President and Chief
Executive Officer of Misonix. "It is our privilege to provide state-of-the-art
head and neck surgery technology to prestigious institutions such as Cleveland's
University Hospitals."
About Misonix Misonix, Inc. designs, develops, manufactures and markets
therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform
is the basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical applications.
Additional information is available on the Company's Web site at
misonix.com.
Safe Harbor Statement With the exception of historical information contained in
this press release, content herein may contain "forward looking statements" that
are made pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based on management's current
expectations and are subject to uncertainty and changes in circumstances.
Investors are cautioned that forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially from the
statements made. These factors include general economic conditions, delays and
risks associated with the performance of contracts, risks associated with
international sales and currency fluctuations, uncertainties as a result of
research and development, acceptable results from clinical studies, including
publication of results and patient/procedure data with varying levels of
statistical relevancy, risks involved in introducing and marketing new products,
potential acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such activities,
the timing of finding strategic partners and implementing such relationships,
regulatory risks including approval of pending and/or contemplated 510(k)
filings, the ability to achieve and maintain profitability in the Company's
business lines, and other factors discussed in the Company's Annual Report on
Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. The Company disclaims any obligation to update its forward-looking
relationships.
Investor Relations Contacts
Misonix Contact:Lytham Partners, LLC
Richard ZarembaRobert Blum, Joe Dorame, Joe Diaz
631-694-9555602-889-9700
invest@misonix.com mson@lythampartners.com
SOURCE Misonix, Inc. |
